Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-...

por Elkord, Eyad, Burt, Deborah J., Sundstedt, Anette, Nordle, Örjan, Hedlund, Gunnar, Hawkins, Robert E.
Publicado 2015